Abbott Laboratories Stock Forecast, Price & News

Abbott Laboratories' stock was trading at $78.09 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ABT shares have increased by 37.8% and is now trading at $107.61.
View which stocks have been most impacted by COVID-19.

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abbott Laboratories in the last year. There are currently 1 sell rating, 4 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Abbott Laboratories or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Abbott Laboratories a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Abbott Laboratories wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Abbott Laboratories is scheduled to release its next quarterly earnings announcement on Wednesday, January 27th 2021.
View our earnings forecast for Abbott Laboratories.

Abbott Laboratories (NYSE:ABT) announced its earnings results on Wednesday, October, 21st. The healthcare product maker reported $0.98 EPS for the quarter, beating the consensus estimate of $0.90 by $0.08. The healthcare product maker had revenue of $8.85 billion for the quarter, compared to the consensus estimate of $8.53 billion. Abbott Laboratories had a net margin of 10.50% and a return on equity of 18.19%. The business's revenue for the quarter was up 9.6% on a year-over-year basis. During the same period in the prior year, the company earned $0.84 earnings per share.
View Abbott Laboratories' earnings history.

Abbott Laboratories declared a quarterly dividend on Thursday, September 17th. Stockholders of record on Thursday, October 15th will be paid a dividend of $0.36 per share on Monday, November 16th. This represents a $1.44 dividend on an annualized basis and a yield of 1.34%. The ex-dividend date is Wednesday, October 14th.
View Abbott Laboratories' dividend history.

Abbott Laboratories updated its FY 2020 Pre-Market earnings guidance on Wednesday, October, 21st. The company provided EPS guidance of 3.55 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.32.

18 brokers have issued 12-month target prices for Abbott Laboratories' stock. Their forecasts range from $94.00 to $130.00. On average, they expect Abbott Laboratories' share price to reach $115.38 in the next year. This suggests a possible upside of 7.2% from the stock's current price.
View analysts' price targets for Abbott Laboratories.

Some companies that are related to Abbott Laboratories include Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), Boston Scientific (BSX), IDEXX Laboratories (IDXX), Baxter International (BAX), ResMed (RMD), DexCom (DXCM), Hologic (HOLX), Teleflex (TFX), Insulet (PODD), STERIS (STE) and Varian Medical Systems (VAR).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Abbott Laboratories investors own include AbbVie (ABBV), Johnson & Johnson (JNJ), NVIDIA (NVDA), AT&T (T), Pfizer (PFE), The Walt Disney (DIS), Cisco Systems (CSCO), Intel (INTC), The Home Depot (HD) and Verizon Communications (VZ).

Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."

Abbott Laboratories' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.63%), State Street Corp (4.16%), Massachusetts Financial Services Co. MA (1.45%), Morgan Stanley (1.43%), Charles Schwab Investment Management Inc. (0.62%) and Nuveen Asset Management LLC (0.53%). Company insiders that own Abbott Laboratories stock include Andrea F Wainer, Andrew H Lane, Brian B Yoor, Brian J Blaser, Christopher J Scoggins, Daniel Gesua Sive Salvadori, Hubert L Allen, Jaime Contreras, Jared Watkin, John F Ginascol, John G Stratton, John M Capek, Joseph J Manning, Lisa D Earnhardt, Mary K Moreland, Michael D Dale, Michael J Pederson, Miles D White, Philip P Boudreau, Randel William Woodgrift, Robert E Funck, Roger Bird, Roxanne S Austin, Sally E Blount, Sharon J Bracken and Stephen R Fussell.
View institutional ownership trends for Abbott Laboratories.

ABT stock was sold by a variety of institutional investors in the last quarter, including CIBC Private Wealth Group LLC, Assenagon Asset Management S.A., Coho Partners Ltd., State Street Corp, Diamond Hill Capital Management Inc., Nuveen Asset Management LLC, State of Tennessee Treasury Department, and KBC Group NV. Company insiders that have sold Abbott Laboratories company stock in the last year include Andrea F Wainer, Andrew H Lane, Brian B Yoor, Christopher J Scoggins, Daniel Gesua Sive Salvadori, Jared Watkin, John F Ginascol, Joseph J Manning, Lisa D Earnhardt, Mary K Moreland, Michael D Dale, Michael J Pederson, Philip P Boudreau, Randel William Woodgrift, Robert E Funck, Roger Bird, and Roxanne S Austin.
View insider buying and selling activity for Abbott Laboratories.

ABT stock was acquired by a variety of institutional investors in the last quarter, including CIBC Private Wealth Group LLC, Massachusetts Financial Services Co. MA, Menora Mivtachim Holdings LTD., Morgan Stanley, DekaBank Deutsche Girozentrale, Railway Pension Investments Ltd, AustralianSuper Pty Ltd, and Bradley Foster & Sargent Inc. CT. Company insiders that have bought Abbott Laboratories stock in the last two years include John G Stratton, and Randel William Woodgrift.
View insider buying and selling activity for Abbott Laboratories.

Shares of ABT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ABT stock can currently be purchased for approximately $107.61.

Abbott Laboratories has a market capitalization of $190.72 billion and generates $31.90 billion in revenue each year. The healthcare product maker earns $3.69 billion in net income (profit) each year or $3.24 on an earnings per share basis. Abbott Laboratories employs 107,000 workers across the globe.

The official website for Abbott Laboratories is www.abbott.com.

Abbott Laboratories' mailing address is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. The healthcare product maker can be reached via phone at 224-667-6100.